Aprotinin reduces cardiac troponin I release and inhibits apoptosis of polymorphonuclear cells during off-pump coronary artery bypass surgery by Bert, C. et al.
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tObjectives: In addition to blood-sparing effects, aprotinin
ay have cardioprotective and anti-inflammatory effects
uring cardiopulmonary bypass–assisted cardiac surgery. In
his study, the authors examined whether aprotinin had
ardioprotective and/or anti-inflammatory effects in pa-
ients undergoing off-pump coronary artery bypass grafting.
Design: A prospective randomized clinical trial.
Setting: University hospital.
Participants: Fifty patients were randomized to control
n  25) or aprotinin treatment (n  25) groups.
Interventions: Aprotinin was given as a loading dose (2 
06 KIU) followed by a continuous infusion at 5  105 KIU/h
ntil skin closure.
Measurements and Main Results: Blood samples for car-
iac troponin I; interleukin-6, interleukin-8, and interleukin-
0; tumor necrosis factor ; and elastase were taken after
nesthesia induction, completion of revascularization, and 6ry
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6 Journal of Cardiothoracamples were taken to assess for apoptosis in polymorpho-
uclear cells. Baseline plasma levels for cardiac troponin I
id not differ between groups but were significantly lower in
protinin-treated patients at the time of revascularization
p  0.03) and 6 hours (p  0.004) and 24 hours (p  0.03)
ater. Aprotinin significantly reduced apoptosis in polymor-
honuclear cells compared with control-treated patients
p  0.04). There were no differences in plasma cytokine or
lastase levels between groups.
Conclusions: The authors conclude that aprotinin reduces
erioperative cardiac troponin I release and attenuates ap-
ptosis in polymorphonuclear cells but has no significant
ffects on plasma cytokine levels in patients undergoing
ff-pump coronary artery bypass graft surgery.
 2008 Elsevier Inc. All rights reserved.
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tors,OTH MECHANICAL INJURY during cardiac surge
and ischemia-reperfusion cause inflammation. In vitro 
eriments report anti-inflammatory effects of aprotinin by m
iple mechanisms, including inhibiting nuclear factor kapp
NFB) activation, protease activated receptor-1 (PAR-1) 
ivation, phospholipase A2 activity, expression of L-selec
ntercellular adhesion molecule-1, and vascular cellular ad
ion molecule.1-6 Neutrophils mediate inflammation-associated
issue damage by binding to activated endothelial cells 
igrating into the surrounding tissues where they release 
eases and oxygen free radicals, leading to tissue dam
nflammatory responses also induce apoptosis of tissue c
otentially leading to altered organ function, and apoptosi
olymorphonuclear (PMN) cells is a key event in resol
cute inflammatory processes. Jimenez7 reported that PMN
ells become apoptosis resistant during systemic inflammat
esponses prolonging the lifespan of these cells. This phen
non is thought to contribute to the organ damage obse
uring systemic inflammatory response syndrome (SIRS) 
elated syndromes. Although cardiopulmonary bypass (CPB)
 major factor eliciting a generalized inflammatory react
nflammation also occurs in off-pump cardiac surgery, be 
 less pronounced way.8-10 Aprotinin has been demonstrated 
educe inflammation in CPB-supported cardiac surgery.11-19
hether aprotinin can further reduce inflammation in off-pu
From the Departments of *Anesthesiology, †Cardiac Surgery, and
Hematology, and ‡Laboratory of Immunology, University Hospital
asthuisberg, Leuven, Belgium.
Address reprint requests to Christophe Bert, MD, PhD, Dienst
nesthesie, OLV Ziekenhuis, Moorselbaan 164, B-9300 Aalst, Belgium.
-mail: christophe.bert@olvz-aalst.be
© 2008 Elsevier Inc. All rights reserved.
1053-0770/08/2201-0005$34.00/0oronary artery bypass graft (OPCAB) surgery has curre
ot been investigated. In addition, aprotinin has been repo
o have cardioprotective properties during cardiac surgery w
PB by reducing ischemia-reperfusion injury, including 
uced cardiac troponin I (cTnI) release in coronary a
ypass graft (CABG) patients.20-24 Reducing inflammatory ac
ivation during surgical trauma and ischemia-reperfusion co
ead to reduced myocardial tissue injury. If, in addition, 
ated PMN cells would become less resistant on apopt
heir reduced lifespan could contribute to decreased tis
njury.
Little data are currently available on the potential cardio
ective and/or anti-inflammatory action of aprotinin in OPC
urgery. T h e authors performed a prospective randomiz
linical trial to evaluate aprotinin’s effects in patients 
ergoing OPCAB surgery using cTnI as a marker of 
ardial damage and interleukin (IL)-6, -8, -10, tumor ne
is factor  (TNF- ), PMN elastase, and PMN cell apopto
s markers of inflammation.
METHODS
After approval by the institutional ethics committee, 50 pat
ndergoing elective OPCAB surgery were enrolled in the study 
ritten informed consent was obtained. Fifty consecutive patients 
ssigned to the control group (n  25) or to the aprotinin group (n
5) by a computer-generated randomization list. Exclusion crit
ere as follows: redo surgery, ejection fraction 30%, chronic immu
osuppressive therapy (including corticosteroids), recent infection, 
table angina, use of coumarin derivatives and GPIIb-IIIa inhibi
ocumented allergy, congenital coagulation disorders, and renal im-
airment (serum creatinine 1.5 mg/dL).
All patients received standard anesthetic care that included premed-
cation with 0.05 mg/kg of lorazepam sublingually 1 hour before
urgery. Anesthesia induction was with midazolam (0.03 mg/kg),
ufentanil (1-1.5 g/kg), propofol target-controlled infusion (starting
ic and Vascular Anesthesia, Vol 22, No 1 (February), 2008: pp 16-22
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17APROTININ DURING OPCAB SURGERYarget concentration of 0.5-1.0 g/mL), and pancuronium (0.1 mg/kg).
nesthesia maintenance was with a continuous propofol infusion (up to
arget concentration of 2.5 g/mL) and supplemental sufentanil (8-10
g/kg) and pancuronium. Vaporizers for volatile anesthetics were
emoved from the ventilator. Patient monitoring included direct arterial
ressure and pulmonary artery pressure monitoring. Patients allocated
o the aprotinin group received a loading dose of 2  106 KIU before
ternotomy, followed by a continuous infusion of 5  105 KIU/h until
ound closure. Heparin was given as anticoagulation to maintain the
ctivated coagulation times 400 seconds. All coronary bypass graft
nastomoses were made with intracoronary shunts in place. The region
o be operated on was immobilized by a regional vacuum stabilizer and,
f needed, by an apical suction device. After revascularization was
omplete heparin was neutralized with protamine (1:1 ratio of active
eparin) and final activated coagulation times were generally within
0% of baseline value. All patients underwent complete revasculariza-
ion. Suctioned blood was washed (Autolog; Medtronic Inc, Minneap-
lis, MN) and returned to the patient if the collected volume exceeded
00 mL. All patients received routine postoperative care. Blood sugar
oncentrations were kept between 70 and 110 mg/dL.
Blood samples for determination of plasma levels of cTnI, IL-6,
L-8, IL-10, TNF-, and elastase were taken after induction of anes-
hesia (T1), after revascularization but before protamine administration
T2), and 6 hours, 12 hours, and 24 hours after revascularization (T3,
4, and T5, respectively). The plasma fraction was isolated by centri-
ugation and stored at 20°C. Blood samples for determination of
olymorphonuclear cell apoptosis (12 controls and 12 aprotinin-treated
atients) were taken at the same time points except for T4 in EDTA-
ontaining tubes and were immediately sent to the laboratory for
nalysis.
The inflammatory cytokines IL-6, IL-8, and IL-10 were measured by
sing cytometric bead array (CBA; BD Biosciences Europe, Erembo-
egem, Belgium) as described by the manufacturer. Acquisition of
ample data was done by using a FACSort (BD Biosciences, San Jose,
A), and results were generated using the BD CBA Analysis Software.
he lowest detection limit for all cytokines was 1.25 pg/mL.
Elastase was determined by sandwich enzyme-linked immunosor-
ent assay (Calbiochem; Merck Biosciences, Nottingham, UK). Sam-
les were measured in duplicate. TNF- was measured in an almost
imilar procedure to elastase by using the TNF- EASIA kit purchased
rom Biosource Europe SA (Nivelles, Belgium). The lowest detection
imits for elastase and TNF- are 0.156 ng/mL and 14.7 pg/mL,
espectively. cTnI plasma levels were determined by a 1-step sandwich
nzyme-linked immunosorbent assay technique and analyzed on a
imension clinical chemistry analyzer (Dade Behring Inc, Brussels,
elgium).
Phosphatidylserine translocation from the inner to the outer cellular
embrane is one of the first phenomenon to occur once apoptosis is
nduced. Annexin V is a naturally occurring high-affinity ligand for PS.
ecause translocation also occurs during necrosis, annexin V is not an
bsolute marker for apoptosis. Therefore, it is often used in conjunction
ith vital dyes, such as propidiumiodide, which bind to nucleic acids
nly when it can penetrate cells through a damaged membrane, thus
istinguishing necrotic from apoptotic cells.
Briefly, blood was collected in a 3-mL EDTA tube and polymor-
honuclear cells separated from the whole blood by using density
radient centrifugation. Obtained PMNs were resuspended in cold
epes buffer at a concentration of 1  106 PMNs per milliliter. Two
undred microliters of this cell suspension were used for analysis. Ten
icroliters of FITC-conjugated annexin V (stock: 20 g/mL) and 20
L propidiumiodide (PI) (stock: 50 L/mL) (BD Biosciences Pharm-
ngen, San Diego, CA) were added. After a gentle vortex, the PMNs
ere incubated for 15 minutes at 4°C in the dark before flow cytometricnalysis. lApoptosis and cell death were measured by using a FACScan flow
ytometer (Becton Dickinson, Erembodegem, Belgium) equipped with
488-nm argon-ion air-cooled laser (15 mW) and standard filter
ombination (FL1 BP 530/30 nm, FL2 BP 585/42 nm, and FL3
P 650 nm) provided by the manufacturer. A minimum of 20,000
vents were collected for each sample. The PMN population was gated
n a forward-scatter versus side-scatter dot plot, and quadrant statistics
ere used on an annexin V versus PI dot plot to express apoptotic
annexin Vpos/PIneg) and dead (annexin Vpos/PIpos) PMNs as fraction of
he total number of PMNs. To calculate absolute numbers, these
ractions were multiplied by the absolute PMN count obtained by a
icros 60 hematology analyzer (ABX Diagnostics, Deurne, Belgium).
ersons involved in blood sample analysis (A.K., V.V.D., J.C., and
.D.) were not aware of the patient’s allocation to either the control
roup or the aprotinin group.
Power analysis was performed on the primary outcome variable
TnI. A difference of 2 ng/mL was considered to be clinically impor-
ant. For a power of 0.8 and   0.05, a sample size of 10 patients for
ach treatment group seemed to be sufficient.
Demographic data and data on blood loss and transfusion were
nalyzed by Student t test. Because plasma levels of interleukins and
lastase were not normally distributed, a Mann-Whitney U test was
sed to look for differences between both groups. Apoptosis results
ere also not normally distributed and treated likewise. cTnI values,
owever, did show a normal distribution and were analyzed by using a
epeated-measures analysis of variance approach. Statistical analysis
as performed with Statistica, release 6.1 (StatSoft Inc, Tulsa, OK).
RESULTS
Demographic data for patients from both study groups are
isted in Table 1. Distribution of age, weight, height, sex, and
reoperative medication were not different between groups.
lso, operating time, number of distal anastomoses (venous
nd arterial), incidence of intramural dissections, and heparin
nd protamine doses were not statistically different (Table 2).
he number of patients who needed pharmacologic support
uring the study period was not statistically different between
roups (Table 2; 9/25 control v 7/25 aprotinin group, p  0.55)
or was the total drug dose. Aprotinin administration did not
Table 1. Demographic and Preoperative Characteristics
Control Aprotinin
Age (y) 67.8 (8.3) 65.7 (10.2)
Weight (kg) 80.6 (9.3) 76.8 (13.9)
Height (cm) 171.5 (9.4) 168.6 (8.7)
Sex ratio (M/F) 20/5 20/5
-adrenergic blockers 17/25 16/25
Calcium channel blockers 6/25 7/25
ACE inhibitors 8/25 5/25
AT II 3/25 2/25
Nitrates 16/25 15/25
Diuretics 3/25 3/25
Bronchodilating agents 0/25 1/25
Acetylsalicylic acid 19/25 18/25
LMWH 6/25 7/25
Statins 19/2 15/25
NOTE. Data are expressed as mean  SD. Patient numbers are
ndicated for sex ratio and preoperative medication. No significant
ifferences were found between groups.
Abbreviations: AT II, angiotensin II inhibitors; LMWH, low–molecu-ar-weight heparins.
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18 BERT ET ALnfluence plasma C-reactive protein levels or serum creatinine
evels throughout the study period (Table 2).
Plasma cTnI results for patients randomized to aprotinin or
ontrol group are shown in Figure 1. There were no differences
n cTnI between groups at baseline (T1). Patients randomized
o the aprotinin group did have a significantly lower cTnI
oncentration after revascularization (T2, p  0.04) and at 6
ours (T3, p  0.004) and 24 hours (T5, p  0.03) after
evascularization compared with controls.
The number of apoptotic PMN cells in both control and
protinin groups are shown in Figure 2. The number of
poptotic PMN cells was lower in the aprotinin group at re-
ascularization (T2, p  0.04) and 6 hours after revasculariza-
ion (T3, p  0.04) compared with the controls. The absolute
umber of white blood cells and PMN cells did not differ
etween groups at any time point (data not shown).
Plasma levels of IL-6, -8, -10; TNF-; and elastase for both
ontrol and treatment groups are shown in Figure 3. For reasons
f scaling nonoutlier ranges are represented by the whiskers.
ull ranges are given in Table 3. In both groups, interleukin and
lastase plasma levels increased from baseline for each time
oint throughout the study period. Peak levels of IL-6, IL-8,
nd TNF- were observed at T3, whereas IL-10 peak levels
ccurred at T4. Plasma elastase levels gradually increased
uring the study period. No significant difference was found in
he plasma concentrations of one of the inflammatory mediators
ested between both groups. Blood loss during the study period
as significantly lower in the aprotinin-treated patients com-
ared with the controls (901 mL mean v 2,131 mL mean, p 
.0003). The volume of reinfused, cell-saved blood was 41 mL
er patient in the aprotinin group versus 242 mL per patient in
he control group (mean per patient, p  0.003). The use of
Table 2. Operative and Postoperative Characteristics
Control Aprotinin p Value
Operating time (min) 260.9 (53.5) 242.4 (51.1) 0.24
Distal anastomoses 2.9 (1.17) 2.8 (1.30) 0.57
Arterial 2.3 (1.14) 2.0 (1.12) 0.32
Venous 0.6 (0.7) 0.7 (1.12) 0.65
Intramural dissection 2/25 3/25 0.64
Heparin dose (IU/kg) 386.2 (169.6) 383.5 (133.8) 0.63
Protamine dose (IU/kg) 306.5 (93.4) 308.5 (105.6) 0.64
Pharmacol. support 9/25 7/25 0.55
Total blood loss (mL) 2132.2 (1487.5) 901.3 (514.6) 0.00029
Washed reinfused blood
per patient (mL) 242.0 (292.0) 41.6 (123.3) 0.0028
Units packed cells per
patient 1.3 (1.34) 0.44 (0.77) 0.0065
CRP (mg/dL)
Preoperative 4.34 (5.04) 3.93 (5.10) 0.8
24-h postoperative 67.54 (27.88) 64.62 (31.87) 0.76
Serum creatinine (mg/dL)
Preoperative 1.22 (0.20) 1.17 (0.24) 0.45
24-h postoperative 1.23 (0.67) 1.09 (0.27) 0.35
NOTE. Data are expressed as mean  SD. Patient numbers are
ndicated for intramural dissection and pharmacologic support.
Abbreviation: CRP, C-reactive protein.acked red cells was significantly reduced in aprotinin-treated
a
aubjects (p  0.0065). One patient from the control group
eeded re-exploration for bleeding.
DISCUSSION
The authors report that perioperative aprotinin administra-
ion during OPCAB surgery resulted in reduced cTnI plasma
evels up to 24 hours postoperatively, indicating reduced myo-
ardial damage in the aprotinin-treated group. These results are
n accordance with prior laboratory and clinical studies sug-
esting that aprotinin reduces the extent of myocardial damage
aused by ischemia-reperfusion injury during CPB-supported
urgery.20-24 More recently, reduced myocardial damage during
PCAB surgery was reported in patients receiving aproti-
in.25,26 Considerable concern exists regarding graft patency
nd graft survival when antifibrinolytics are used during coro-
ary bypass surgery. However, several meta-analyses studying
n-pump CABG did not find any evidence supporting this
oncern.27,28 This is in agreement with the present observation
n OPCAB surgery that aprotinin treatment resulted in reduced
TnI concentrations. In contrast, a recently published multi-
enter observational study showed an increased risk for renal
ailure, stroke, and cardiac failure associated with the use of
protinin in CABG surgery.29 However, caution must be used
hen interpreting the results of the study by Mangano et al.29
major limitation of the study is the absence of randomization
esulting in an almost 2-fold higher incidence of complex
urgery in the aprotinin group.
A possible mechanism was reported very recently by Khan
nd coworkers.30 They found that aprotinin treatment resulted
n the preservation of coronary endothelial adherens junctions
esulting in reduced tissue edema after regional ischemia and
ardioplegic arrest. Another possible way of cardioprotection
elies on aprotinin’s ability to block the PAR-1 receptor. This
Fig 1. Time course of cTnI plasma levels in both control and
protinin groups. Data are expressed as mean  standard deviation.
1-T5 indicate time points; see text for explanation. Circles: control
roup; triangles: aprotinin group; , significant difference between
protinin group and control group (p values: T2  0.04, T3  0.004,
nd T5  0.03).
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19APROTININ DURING OPCAB SURGERYas recently been described to occur in patients undergoing
ardiothoracic surgery.31 This PAR-1 receptor is the classic
hrombin receptor, and its activation converts endothelial cells
nto a proinflammatory state with subsequent recruitment and
ctivation of PMN cells. Recently, Khan et al32 showed that
protinin inhibits protease-dependent platelet aggregation and
hrombosis, which was, at least in part, mediated by PAR-1
nhibition. Platelet aggregation is associated with the release of
roinflammatory mediators, and hence reduced platelet aggre-
ation may contribute to a reduced local proinflammatory sta-
us. Poston et al25 recently suggested that aprotinin might have
n antithrombotic action in addition to its antifibrinolytic effect.
he potential anti-inflammatory actions of aprotinin could also
ontribute to a reduced myocardial invasion of activated gran-
locytes. The exact mechanism by which aprotinin reduces the
erioperative cTnI release in OPCAB surgery is currently un-
nown and needs further investigation. Finally, this study adds
o the fact that aprotinin use in primary cardiac surgery appears
o be safe with regard to graft patency.
In this study, the authors describe, for the first time, an
ntiapoptotic effect of aprotinin on PMN cells in vivo. Trevani
t al33 previously showed that aprotinin was able to prevent
rotease-induced apoptosis of neutrophils in vitro. They did not
tudy whether this effect was mediated through inactivation of
he proteases or by inhibition of PAR-1 activation. It has been
hown that apoptosis of PMN cells is an important phenome-
on in the termination of acute inflammatory processes. In
ddition, the occurrence of apoptotic resistance in PMN cells
as been shown in patients suffering from SIRS and after major
urgery.7,34 In view of the potential anti-inflammatory actions
f aprotinin, it was expected that aprotinin would rather en-
ance PMN cell apoptosis. Nonetheless, the opposite was ob-
erved. Apparently aprotinin further enhanced apoptotic resis-
ance in PMN cells after cardiac surgery. Whether this
ntiapoptotic effect of aprotinin further contributes to the de-
elopment of systemic inflammation by prolonging the lifespan
f PMN cells is currently unknown. These findings are inter-
sting in view of the study by Mangano et al29 reporting an
ncreased incidence of serious side effects when aprotinin is
sed during CABG surgery. It could be possible that the apro-
inin-induced increased life span of PMN cells constitutes a
ontributing factor in the increased incidence of serious post-
perative morbidity and hence aprotinin would have opposing
Fig 2. Evolution of absolute
umber of apoptotic PMN cells
n the control and aprotinin
roups. Solid boxes indicate
edian; open boxes indicate
5th and 75th percentiles. Whis-
ers indicate range. T1, T2, T3,
nd T5 indicate time points; see
ext for explanation. At T2 and
3, numbers of apoptotic PMN
ells are significantly different
etween groups (p  0.04 for
oth time points).ffects. nAs shown in the results section, no significant modulatory
ffect of aprotinin was observed on the plasma levels of the
tudied inflammatory mediators. Many, but not all, studies in
PB-supported cardiac surgery have provided evidence for an
nti-inflammatory action of aprotinin.11-19,35-37 There seems to
e conflicting evidence as to the presumed anti-inflammatory
ctions of aprotinin. On a theoretical basis and largely con-
rmed by in vitro investigations, aprotinin has potential anti-
nflammatory actions.1-6 However, in the clinical setting, the
icture is less clear. No literature data with regard to the
otential anti-inflammatory action of aprotinin during OPCAB
urgery are available thus far. Because inflammation also oc-
urs in OPCAB surgery, be it less pronounced compared with
n-pump CABG surgery, OPCAB patients remain at risk for a
omplicated postoperative course.8-10 In this study in OPCAB
atients, the authors failed to show an effect of aprotinin on the
nflammatory mediators tested. It may be that the absence of
ontact activation in the OPCAB procedure makes the anti-
nflammatory action of aprotinin less pronounced. It is well
nown that one of the major pathways of aprotinin action is
hrough inhibition of contact activation. A major limitation of
he present study is that only a subset of inflammatory media-
ors has been determined at the expense of others such as those
nvolved in the complement pathway. Also, the effect of cell
aving on the plasma levels of inflammatory mediators is not
ell characterized. Two studies report more than 90% elimi-
ation of platelets, heparin, and proteins by the Autolog de-
ice.38,39 These studies report different elimination ratios for
eukocytes of 78% and 91%. The higher blood loss in the
ontrol group and consequently the more frequent washing of
hed blood in this group may have diminished the total load of
nflammatory mediators, masking the anti-inflammatory effect
f aprotinin. This reduced mediator load upon washing of
uctioned blood has also been suggested by other authors.40
In addition, the authors confirmed an important reduction in
lood loss and use of allogeneic blood transfusion in patients
eceiving aprotinin. This blood-sparing effect has been shown
n major surgery for at least 2 decades and has recently been
onfirmed during OPCAB surgery as well.25,41
From this study, it can be concluded that perioperative apro-
inin administration in patients undergoing OPCAB reduces the
erioperative cTnI release and hence may confer cardioprotec-
ion. The clinical significance of this observation is currently
ot known nor is the mechanism by which aprotinin evokes this
m20 BERT ET ALFig 3. Evolution over time of IL-6, -8, -10, TNF-, and elastase plasma levels in both control and aprotinin groups. Solid boxes indicate
edian; open boxes indicate 25th and 75th percentiles. Whiskers indicate nonoutlier range. T1-T5 indicate time points; see text for explanation.
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21APROTININ DURING OPCAB SURGERYffect. In addition, an antiapoptotic effect of aprotinin was seen
n PMN cells without any effect on the plasma levels of several
Table 3. Ranges of IL-6, IL-8, IL-10, TNF-, and Elastase Plasma Le
T1 T2
IL-6 (ng/mL)
Control 1.10-6.30 3.0-65.50
Aprotinin 1.20-5.20 3.0-88.9
p value 0.873 0.424
IL-8 (ng/mL)
Control 1.30-5.90 2.20-9.30
Aprotinin 1.80-7.50 2.00-16.20
p value 0.184 0.051
IL-10 (ng/mL)
Control 1.40-3.10 1.10-4.40
Aprotinin 1.20-2.70 1.00-7.50
p value 0.092 0.682
TNF- (ng/mL)
Control 6.09-44.39 9.30-41.57
Aprotinin 9.57-35.83 9.19-36.04
p value 0.676 0.987
Elastase (pg/mL)
Control 34.40-135.50 28.30-261.80
Aprotinin 25.00-347.10 28.00-167.00
p value 0.120 0.334nflammatory mediators. The authors also confirmed the blood- n
REN
ystemic proinflammatory cytokines after off-pump versus conven-
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1aving effect of aprotinin in patients undergoing OPCAB sur-
ery. Further clinical trials are needed to explore whether aproti-
in Both Control and Treatment Groups and p Values Are Shown
T3 T4 T5
70.40-2,112 33.8-991 19-691
85.2-1,558.5 87.6-784.5 35.6-601
0.107 0.196 0.776
11.0-156.3 5.50-91.50 5.0-52.30
13.70-72.20 9.50-52.30 6.50-31.00
0.141 0.168 0.422
2.50-39.60 3.10-58.10 1.80-29.40
1.70-23.30 3.10-73.60 2.60-19.20
0.123 0.347 0.588
11.86-176.45 9.20-89.97 6.47-68.88
12.30-124.75 10.38-41.29 8.21-36.20
0.699 0.440 0.573
52.80-1095.60 71.40-230.10 76.10-397.00
58.60-304.00 55.90-747.20 80.20-1269.00
0.286 0.546 0.261in administration in OPCAB patients is clinically beneficial.REFE
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